• Explore /
  • Poster
  • / BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.

BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.

Abstract Poster

Authors

null

Michael Wang

University of Texas MD Anderson Cancer Center, Houston, TX

Michael Wang , Toby A. Eyre , Nirav Niranjan Shah , Steven Le Gouill , Martin H. Dreyling , Elisabeth Vandenberghe , Yucai Wang , Chan Cheah , Yuqin Song , Mitul Gandhi , Christopher H. Chay , Jeff Porter Sharman , David Jacob Andorsky , Amy S. Ruppert , Chi-Wei Duann , Valerie A. Muthig , Rodrigo Ito , Wojciech Jurczak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04662255

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7587)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7587

Abstract #

TPS7587

Poster Bd #

133b

Abstract Disclosures

Similar Posters

First Author: George Follows

First Author: Jennifer Ann Woyach

First Author: Martin H. Dreyling

First Author: Michael Wang